https://www.selleckchem.com/pr....oducts/Dasatinib.htm
rsement and access to this treatment. For patients with HR+/HER2- ABC, ribociclib plus fulvestrant is projected to result in substantial gains in QALYs compared with fulvestrant. At its current list price, ribociclib used in combination with fulvestrant is likely to be cost effective in these patients at a threshold ICER of $157,343. These results may be useful in deliberations regarding reimbursement and access to this treatment.Iron-overload cardiomyopathy is the principal cause of mortality in thalassemia. Via feature-tracking card
Like
Comment
Share
